W
WAVEMAN · COMPANY
MIRM · Mirum Pharmaceuticals, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

MIRM

Mirum Pharmaceuticals, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001759425
FORM 144 · 9☆ WATCH
INSIDER NET · 180D
-$24.8M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
191
13F, latest reported quarter
REVENUE GROWTH
+54.7%
XBRL, annual
NET MARGIN
-4.5%
CONVERSIONS · 180D
22
codes C/M, not in net · $1.1M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$24.8M over 180 days
-$13.9M over 90 days
below 90% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
191 funds added or opened last quarter
more than 86% of Pharma & Biotech
REVENUE
+54.7% year over year
more than 80% of Pharma & Biotech
MARGIN
-4.5% net margin
more than 61% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
10.5% of shares outstanding short · 12.1 days to cover · settled 2026-07-31
more than 79% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$24.8M across 6 people in 180 days.
191 funds added or opened positions in the latest 13F quarter, of 331 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +35.7%
+35.7%12M
-14%+15%+44%+73%2025-092025-102025-122026-032026-052026-072026-09 2026-01-23 · Heron Patrick J bought $9.0M2026-08-18 · Howe Jolanda sold $4.0M2025-12-19 · GREY MICHAEL G sold $3.9M2026-03-16 · Peetz Christopher sold $3.8M2025-12-01 · GREY MICHAEL G sold $3.7M2025-11-21 · GREY MICHAEL G sold $3.5M2026-09-01 · Peetz Christopher sold $2.1M2026-06-01 · Peetz Christopher sold $1.6M2026-03-16 · Radovich Peter sold $1.5M2026-07-06 · Peetz Christopher sold $1.5M2025-09-11 · Brege Laura sold $1.2M2026-08-10 · Peetz Christopher sold $1.2M2026-02-02 · Peetz Christopher sold $940.9K2026-09-01 · Peetz Christopher sold $815.2K2025-09-12 · BJERKHOLT ERIC sold $728.0K2026-03-16 · BJERKHOLT ERIC sold $670.3K2026-03-16 · Quan Joanne sold $670.3K2026-06-01 · Peetz Christopher sold $665.9K2026-01-22 · Peetz Christopher sold $662.5K2026-01-26 · Peetz Christopher sold $657.1K2026-01-20 · Quan Joanne sold $623.9K2026-08-11 · BJERKHOLT ERIC sold $599.5K2026-08-10 · Peetz Christopher sold $597.2K2026-07-06 · Peetz Christopher sold $511.5K2026-03-16 · Howe Jolanda sold $435.2K2025-12-22 · Ramasastry Saira sold $400.0K2026-06-01 · Ramasastry Saira sold $397.7K2026-07-06 · BJERKHOLT ERIC sold $380.1K2026-07-01 · Howe Jolanda sold $326.5K2026-01-26 · Radovich Peter sold $302.3K2026-02-02 · Radovich Peter sold $271.8K2026-06-17 · Howe Jolanda sold $264.5K2026-06-01 · Peetz Christopher sold $246.3K2026-07-06 · Peetz Christopher sold $244.4K2026-08-10 · Peetz Christopher sold $230.3K2026-01-22 · Radovich Peter sold $222.3K2026-05-15 · Ramasastry Saira sold $218.9K2026-07-06 · Peetz Christopher sold $213.4K2026-06-08 · BJERKHOLT ERIC sold $209.6K2026-02-13 · Ramasastry Saira sold $204.2K2026-04-15 · Ramasastry Saira sold $193.8K2026-08-03 · Howe Jolanda sold $193.7K2026-09-02 · JOLANDA MARIE HOWE filed to sell $65.8K2026-09-01 · CHRISTOPHER PEETZ filed to sell $3.0M2026-08-18 · JOLANDA MARIE HOWE filed to sell $4.0M2026-08-11 · ERIC BJERKHOLT filed to sell $599.5K2026-08-10 · CHRISTOPHER PEETZ filed to sell $2.0M2026-08-03 · JOLANDA MARIE HOWE filed to sell $193.7K2026-07-06 · ERIC BJERKHOLT filed to sell $611.3K2026-07-06 · CHRISTOPHER PEETZ filed to sell $2.4M2026-07-01 · JOLANDA MARIE HOWE filed to sell $326.5K
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $24.8M sold by insiders over 180 days, 191 funds added last quarter, $13.2M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Mirum Pharmaceuticals, Inc. insiders sold a net $24.8M of stock across 166 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Howe Jolanda
SVP, GLOBAL CONTROLLER
SELL
2026-09-02
658.0
$65.8K
Peetz Christopher
CHIEF EXECUTIVE OFFICER
SELL
2026-09-01
8,312.0
$815.2K
Peetz Christopher
CHIEF EXECUTIVE OFFICER
SELL
2026-09-01
21,688.0
$2.1M
Howe Jolanda
SVP, GLOBAL CONTROLLER
SELL
2026-08-18
40,000.0
$4.0M
BJERKHOLT ERIC
CHIEF FINANCIAL OFFICER
SELL
2026-08-11
6,001.0
$599.5K
166 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 161 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Frazier Life Sciences Management, L.P.
7,679,684.0 sh
$899.1M
Jupiter Topco LLC
5,909,184.0 sh
$691.7M
BlackRock, Inc.
4,390,063.0 sh
$513.9M
FMR LLC
3,670,314.0 sh
$429.7M
VANGUARD PORTFOLIO MANAGEMENT LLC
2,377,019.0 sh
$278.3M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
JOLANDA MARIE HOWE
FILED 2026-09-02
$65.8K
CHRISTOPHER PEETZ
FILED 2026-09-01
$3.0M
JOLANDA MARIE HOWE
FILED 2026-08-18
$4.0M
ERIC BJERKHOLT
FILED 2026-08-11
$599.5K
CHRISTOPHER PEETZ
FILED 2026-08-10
$2.0M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
F/m Emerald Life Sciences Innovation ETF
$4.6M POSITION · AS OF 2026-02-28
4.8%
Eventide Healthcare & Life Sciences Fund
$63.8M POSITION · AS OF 2026-03-31
4.0%
ALPS Medical Breakthroughs ETF
$4.2M POSITION · AS OF 2026-02-28
3.1%
Nomura Small Cap Growth Fund
$25.6M POSITION · AS OF 2026-03-31
2.6%
SFT Nomura Small Cap Growth Fund
$4.1M POSITION · AS OF 2026-03-31
2.6%
Nomura VIP Small Cap Growth Series
$4.7M POSITION · AS OF 2026-03-31
2.5%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 23 registered trials, 12 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
1 ACTIVE
8
Phase 2
3 ACTIVE
9
Phase 3
3 ACTIVE
1
Phase 4
1 ACTIVE
2
Not applicable
2 ACTIVE
2
Multi-phase
2 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return · Christopher Peetz
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$10.4M
$29.7M
$3.5M
+395%
+25%
2024
$6.6M
$13.0M
$3.0M
+159%
-7%
2023
$6.5M
$9.4M
$3.4M
+85%
-6%
2022
$4.4M
$6.5M
$1.5M
+22%
-10%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$521.3M$336.9M$186.4M$77.1M
OPERATING INCOME$-22.1M$-87.6M$-109.2M$-131.2M
NET INCOME$-23.4M$-87.9M$-163.4M$-135.7M
EPS (DILUTED)-0.47-1.85-4.00-4.02
OPERATING CASH FLOW$55.8M$10.3M$-70.9M$-120.1M
CASH$296.7M$222.5M$286.3M$28.0M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →